Dihydroergotamine mesylate (Standard)
Dihydroergotamine (mesylate) (Standard) is the analytical standard of Dihydroergotamine (mesylate). This product is intended for research and analytical applications. Dihydroergotamine mesylate is a BBB-permeable ergot alkaloid that can be used for the research of migraines.
For research use only. We do not sell to patients.
- Purity: 98%
- CAS No.: 6190-39-2
- Formula: C₃₄H₄₁N₅O₈S
- Molecular Weight:679.78
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Product Information
-
Chemical Information
- Purity & Documentation
-
Help & FAQs
Product Information
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
Chemical Information
-
CAS No. 6190-39-2
-
Molecular Weight 679.78
-
Formula C₃₄H₄₁N₅O₈S
-
SMILES
O[C@@]([C@@](CCC1)([H])N1C2=O)(O[C@](NC([C@@H](CN(C)[C@]3([H])C4)C[C@]3([H])C5=C6C4=CNC6=CC=C5)=O)(C)C7=O)N7[C@H]2CC8=CC=CC=C8.CS(=O)(O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Colman, I., et al., Parenteral dihydroergotamine for acute migraine headache: a systematic review of the literature. Ann Emerg Med, 2005. 45(4): p. 393-401. [Content Brief]
[2]. Saper, J.R., et al., DHE in the pharmacotherapy of migraine: potential for a larger role. Headache, 2006. 46 Suppl 4: p. S212-20. [Content Brief]
[3]. Schaerlinger, B., et al., Agonist actions of dihydroergotamine at 5-HT2B and 5-HT2C receptors and their possible relevance to antimigraine efficacy. Br J Pharmacol, 2003. 140(2): p. 277-84. [Content Brief]
[4]. Chang SH, et al. Dihydroergotamine Tartrate Induces Lung Cancer Cell Death through Apoptosis and Mitophagy. Chemotherapy. 2016;61(6):304-12. [Content Brief]
[5]. He M, et al. Dihydroergotamine mesylate enhances the anti-tumor effect of sorafenib in liver cancer cells. Biochem Pharmacol. 2023 May;211:115538. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Dihydroergotamine mesylate (Standard) Related Classifications
HY-B0670AR Related Classifications
Powered by Bioz